9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy (2021)
Attributed to:
Enhancing immunogenicity in non-viral low mutation burden tumours
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41467-021-25894-9
PubMed Identifier: 34556668
Publication URI: http://europepmc.org/abstract/MED/34556668
Type: Journal Article/Review
Parent Publication: Nature Communications
Issue: 1
ISSN: 2041-1723